Beam Therapeutics is a biotechnology company developing precision genetic medicines based on base editing, a form of CRISPR-related gene editing that can rewrite single DNA bases without fully cutting the double helix. Its pipeline targets genetic diseases and other conditions where correcting point mutations or regulating genes may offer durable treatment. The platform aims for more precise edits with potentially fewer unintended effects than traditional nuclease approaches. Partners and collaborators help advance selected programs toward the clinic.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q1 2025 | 7.5 | — | -108.3 | — |
| Q2 2025 | 8.5 | — | -102.1 | — |
| Q3 2025 | 9.7 | — | -112.7 | — |
| Q4 2025 | 114.1 | — | 244.3 | — |
| Q1 2026 | 31.7 | 324.9% | -94.3 | — |
| Q2 2026 | 0.5 | -94.2% | -122.7 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: OneSpaWorld Holdings Limited (OSW), H2O America (HTO), Payoneer Global Inc. (PAYO), Five9, Inc. (FIVN), Kaiser Aluminum Corporation (KALU), Newell Brands Inc. (NWL)